Cargando…
The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
BACKGROUND AND AIMS: The composition of the human gut microbiota is linked to health and disease, and knowledge of the impact of therapeutics on the microbiota is essential to decipher their biological roles and to gain new mechanistic insights. Here we report the effect of aldafermin, an analog of...
Autores principales: | Loomba, Rohit, Ling, Lei, Dinh, Duy M., DePaoli, Alex M., Lieu, Hsiao D., Harrison, Stephen A., Sanyal, Arun J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898628/ https://www.ncbi.nlm.nih.gov/pubmed/32794259 http://dx.doi.org/10.1002/hep.31523 |
Ejemplares similares
-
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases
por: Sanyal, Arun J., et al.
Publicado: (2021) -
Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021) -
Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice
por: Aoki, Ryo, et al.
Publicado: (2021) -
FGF19 and FGF21: In NASH we trust
por: Talukdar, Saswata, et al.
Publicado: (2020) -
Current therapies and new developments in NASH
por: Dufour, Jean-François, et al.
Publicado: (2022)